156 related articles for article (PubMed ID: 12536989)
1. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population.
Niewinski P; Orzechowska-Juzwenko K; Hurkacz M; Rzemislawska Z; Jaźwinska-Tarnawska E; Milejski P; Forkasiewicz Z
Eur J Clin Pharmacol; 2002 Nov; 58(8):533-5. PubMed ID: 12536989
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 and GSTM1 genotypes in a Polish population.
Gawronska-Szklarz B; Wójcicki M; Kuprianowicz A; Kedzierska K; Kedzierski M; Górnik W; Pawlik A
Eur J Clin Pharmacol; 1999 Jul; 55(5):389-92. PubMed ID: 10456489
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
5. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.
Bagheri A; Kamalidehghan B; Haghshenas M; Azadfar P; Akbari L; Sangtarash MH; Vejdandoust F; Ahmadipour F; Meng GY; Houshmand M
Drug Des Devel Ther; 2015; 9():2627-34. PubMed ID: 25999696
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.
López M; Guerrero J; Jung-Cook H; Alonso ME
Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913
[TBL] [Abstract][Full Text] [Related]
10. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype.
Chen SQ; Wedlund PJ
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):585-8. PubMed ID: 10678117
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
[TBL] [Abstract][Full Text] [Related]
12. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
Buzková H; Pechandová K; Slanar O; Perlík F
Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
15. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
16. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 genotype determination in the Danish population.
Brøsen K; Nielsen PN; Brusgaard K; Gram LF; Skjødt K
Eur J Clin Pharmacol; 1994; 47(3):221-5. PubMed ID: 7867674
[TBL] [Abstract][Full Text] [Related]
20. Genetically determined sparteine oxidation polymorphism in a Polish population.
Orzechowska-Juzwenko K; Pawlik J; Niewiński P; Milejski P; Dembowski J; Turek J; Goździk A; Swiebodzki L; Hora Z
Eur J Clin Pharmacol; 1994; 46(5):481-3. PubMed ID: 7957549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
